Methods of reducing mammographic breast density and/or breast cancer risk

A technique for mammography, breast density, applied in the fields of reducing breast pain, androgen agents and aromatase inhibitors, reducing elasticity and/or reducing breast cell genome mechanics signaling, aromatase inhibitors

Active Publication Date: 2017-11-28
HAVAH THERAPEUTICS PTY LTD
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] Another problem in the prior art is the number of cysts (cysts) found in the breasts of some patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of reducing mammographic breast density and/or breast cancer risk
  • Methods of reducing mammographic breast density and/or breast cancer risk
  • Methods of reducing mammographic breast density and/or breast cancer risk

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0414] Example 1: Dose Administration Algorithm

[0415] Using the following dosage administration algorithm, subcutaneous granules containing a combination of testosterone and anastrozole were used to treat menopausal symptoms in 50-year-old women with high mammographic breast density, including painful breast cysts. After 1 year of treatment, the improvement of MBD was observed through mammography ( figure 1 Is a mammogram of the patient’s breast taken immediately before treatment, and figure 2 It is a mammogram of the patient's breast at 1 year (ie after 1 year of treatment).

[0416] FAI is calculated according to the formula, in which serum measurements of total testosterone and sex hormone binding protein are calculated by radioimmunoassay. The serum levels of aromatase inhibitors were determined by liquid chromatography-tandem mass spectrometry.

[0417] Dose schedule

[0418] Initial dose administration

[0419] Initial dose administration (androgen agent): TD=BW X TBF X MBD...

Embodiment 2

[0447] Example 2: Serum Anastrozole

[0448] Thirty women with high MDB have been treated in the past 18 months, and 20 of them must receive 2 mammograms for evaluation at baseline and 1 year (Table 1). Table 1 provides median values. All 30 women were drawn serum for serum testosterone and sex hormone binding protein at baseline and 1 year, so that the free androgen index (FAI=total testosterone level divided by sex hormone binding protein level can be calculated, and then multiplied by 100 to provide the percentage ). Serum anastrozole was calculated by liquid chromatography-tandem mass spectrometry.

[0449]

[0450]

[0451] Table 1

[0452] This example shows that the combination of testosterone and anastrozole administered subcutaneously at an interval of 4 months resulted in an increase in serum anastrozole within the treatment range and an increase in testosterone in the high physiological range (normal range is usually 0.2-7%). Valley level (as measured by FAI). Among t...

Embodiment 3

[0453] Example 3: Evaluation of breast stiffness reduction using mammography

[0454] Techniques have been developed that allow estimation of breast tissue stiffness based on variables from mammography. For example, this method is proposed in Boyd and the present disclosure. image 3 Show how to estimate the hardness of breast tissue based on the volume and area measurements described above by making three assumptions. First of all, this technology considers that the breast volume and projected area measured on the extruded breast are basically accurate measurements of these entities. It is also assumed that the shape of the uncompressed breast can be represented by a hemisphere and the shape of the mammography area can be represented by a semicircle. Regardless of the assumed shape, the measured breast volume remains essentially unchanged. The assumption that the shape of the uncompressed breast is a hemisphere enables the radius of the hemisphere to be calculated for comparis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
hardnessaaaaaaaaaa
Login to view more

Abstract

The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-memopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reducing elasticity and/or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.

Description

Technical field [0001] The present disclosure generally relates to a method for reducing mammography mammary gland density and / or breast stiffness in warm-blooded animals (eg, women, such as premenopausal, perimenopausal, or postmenopausal women), the method comprising administering an effective amount An effective amount of male hormones and aromatase inhibitors. The present disclosure also relates to reducing breast pain. The present disclosure also relates to methods for reducing elasticity and / or reducing mammary cell genome mechanical signal transduction. The present disclosure also relates to providing effective amounts of androgen agents and aromatase inhibitors to breast tissue, thereby stabilizing and / or increasing the expression level of androgen receptor. The present disclosure also relates to reducing the risk of breast cancer in warm-blooded animals by administering effective amounts of androgen agents and effective amounts of aromatase inhibitors to certain warm-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/568A61K31/585A61K31/4196A61K31/5685A61P43/00A61P35/00
CPCA61K45/06A61K31/4196A61K31/568A61K31/569A61P29/00A61P35/00A61P43/00A61K9/0053A61K9/0024
Inventor 斯蒂芬·奈杰尔·比勒尔
Owner HAVAH THERAPEUTICS PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap